CholiClean

<style>.sc-desc{color:#3F524A;font-size:16px;line-height:1.65}.sc-desc__lead{max-width:72ch}.sc-desc__lead p{margin:0 0 14px}.sc-desc__lead p:first-child{font-size:18px;color:#14342B}.sc-desc__card{background:#fff;border:1px solid #E6EAE6;border-radius:14px;padding:22px 24px;margin-top:22px;box-shadow:0 1px 2px rgba(20,52,43,.04)}.sc-desc__card--claims{background:#F7FAF7;border-color:#DBE5DE}.sc-desc__h{margin:0 0 12px;font-size:17px;font-weight:700;color:#14342B;letter-spacing:-.01em}.sc-desc__p{margin:0 0 12px}.sc-desc__p:last-child{margin-bottom:0}.sc-desc__checks{list-style:none;margin:0;padding:0}.sc-desc__checks li{position:relative;padding:7px 0 7px 32px}.sc-desc__checks li::before{content:'';position:absolute;left:0;top:10px;width:20px;height:20px;border-radius:50%;background:#EDF2EE url("data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2024%2024'%20fill='none'%20stroke='%231F6B4F'%20stroke-width='3.2'%20stroke-linecap='round'%20stroke-linejoin='round'%3E%3Cpath%20d='M5%2012.5l4.2%204L19%207'/%3E%3C/svg%3E") center/11px 11px no-repeat}.sc-desc__dots{margin:0;padding-left:20px}.sc-desc__dots li{padding:3px 0}.sc-desc__callout{display:flex;gap:14px;background:#EEF4F2;border:1px solid #D8E5E0;border-radius:12px;padding:18px 20px;margin-top:22px}.sc-desc__callout--care{background:#FBF6EC;border-color:#ECDDBE}.sc-desc__callout--care .sc-desc__h{color:#7E6418}.sc-desc__callout__icon{flex:0 0 auto;width:26px;height:26px;border-radius:50%;background:#1F6B4F;color:#fff;font-weight:700;font-size:15px;line-height:26px;text-align:center}.sc-desc__callout--care .sc-desc__callout__icon{background:#C99A2E}.sc-desc__callout .sc-desc__h{margin-bottom:8px}</style><div class="sc-desc"><section class="sc-desc__card"><h3 class="sc-desc__h">CHOLICLEAN</h3><p class="sc-desc__p">Non-alcoholic fatty liver disease (NAFLD) is characterised by an abnormal accumulation of triglycerides in at least 5% of hepatocytes. It is strongly linked to the obesity and diabetes epidemics and to metabolic syndrome.</p><p class="sc-desc__p">The accumulation of triglycerides in the liver (NAFLD) can worsen, if not managed, into non-alcoholic steatohepatitis (NASH), which can in turn progress to fibrosis, cirrhosis and liver cancer.</p><p class="sc-desc__p">Based on numerous scientific publications, Laboratoires Fenioux has scrupulously selected 5 relevant ingredients suited to the management of NASH:</p><p class="sc-desc__p">Lactobacillus fermentum (ME3 ®):</p><p class="sc-desc__p">Regulates blood lipids (triglycerides and cholesterol) and blood sugar levels</p><p class="sc-desc__p">Reduces liver inflammation</p><p class="sc-desc__p">Stimulates glutathione production</p><p class="sc-desc__p">Choline:</p><p class="sc-desc__p">Transports lipids out of the liver</p><p class="sc-desc__p">Stimulates bile excretion</p><p class="sc-desc__p">Silymarin (milk thistle):</p><p class="sc-desc__p">Reduces fibrosis and steatosis</p><p class="sc-desc__p">Promotes liver regeneration</p><p class="sc-desc__p">Reduces insulin resistance</p><p class="sc-desc__p">Berberine:</p><p class="sc-desc__p">Hypolipidaemic effect</p><p class="sc-desc__p">Hypoglycaemic effect</p><p class="sc-desc__p">Inhibits liver inflammation and oxidation</p><p class="sc-desc__p">Glucoraphanin (broccoli):</p><p class="sc-desc__p">Activates the Nrf2 pathway</p><p class="sc-desc__p">Preserves mitochondrial function</p><p class="sc-desc__p">Increases hepatic β-oxidation</p></section></div>